mRNA-1644v2-Core
/ Moderna, IAVI
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 01, 2024
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
(clinicaltrials.gov)
- P1 | N=56 | Active, not recruiting | Sponsor: International AIDS Vaccine Initiative | Trial completion date: Jul 2023 ➔ Jul 2024
Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD4
1 to 1
Of
1
Go to page
1